GEHC
Same thesis, slightly less enthusiasm
Piper Sandler just shaved its price target on GE HealthCare Technologies to $88 from $96, but left the Overweight rating intact. Translation: the firm still thinks the medtech story works, it just doesn’t want to pay as much for the same plot twist.
Why you should care
For investors, this kind of note matters because it can reset expectations without changing the underlying narrative. GEHC was up 2.91% in the premarket-ish real-time screen at $75.33, so the new target still leaves room for upside — but the pattern here is clear: analysts have been ratcheting down targets across the board lately.
The vibes check
This follows a little parade of target cuts:
- BTIG to $85 from $91
- Mizuho to $90 from $95
- Goldman Sachs to $81 from $97
- Citigroup to $80 from $84
- Evercore ISI to $85 from $98
That doesn’t automatically mean something is broken. But when multiple shops keep nudging targets lower, it usually means the easy upside got priced out and the market needs a fresher catalyst.
Big picture
GE HealthCare is still being treated like a quality name in advanced medical equipment, just one that isn’t getting the same generous multiple it used to. In other words: the bull case is alive, but the dance floor is getting a little more crowded.